The hypertension market is one of the largest in the global pharmaceutical industry, with continued prospects for high revenue generation and market growth.
The hypertension market is facing great challenges in terms of strong internal competition and patent expiration with a concomitant generic threat. The angiotensin II antagonists have provided an improved balance of efficacy and tolerability in recent years, it is possible that even newer classes of antihypertensive – such as the renin inhibitors – will also provide great therapeutic and commercial scope. Given the great challenges of treating hypertension, continued investment into the development of improved treatments is required, as well as basic scientific research into the disorder. Recent developments in both the pharmaceutical industry and the public sector provide scope for optimism.
The market for hypertensives – led by the angiotensin II antagonists – is one of the largest and most profitable in the global pharmaceutical market, with total anti-hypertensive sales of $36600m in 2006. Hypertension, or high blood pressure, is a worldwide epidemic: by 2025 vision gain predict that worldwide there will be more than 1.5 billion sufferers of this disease. Modern lifestyles, such as poor diet and lack of exercise, are the main contributory factors to elevated blood pressure. Consequently, the incidence and prevalence of hypertension are increasing rapidly in both developed and developing countries.
In 2005, The Lancet reported that more than 330 million adults in Europe and North America suffer from high blood pressure. With many more in the developed world the Hypertension market is still relatively untapped
According to the World Health Organisation, approximately 80% of people with high blood pressure have additional uncontrolled cardiovascular risks. Hypertension is also strongly age-dependent, with older people being far more susceptible. Aging populations worldwide therefore constitute a further driver in this prominent market.